FDA Approves Belumosudil for Chronic GVHD

On July 16, 2021, the U.S. Food and Drug Administration (FDA) approved belumosudil, a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy.

Read the FDA announcement.

Read the Kadmon Holdings, Inc. announcement.

Posted 7/19/2021